Varespladib sodium is primarily investigated for its potential therapeutic applications in treating inflammatory and autoimmune diseases. It acts as a potent inhibitor of secretory phospholipase A2 (sPLA2), an enzyme involved in the inflammatory response. By blocking sPLA2, it reduces the production of pro-inflammatory mediators, making it a promising candidate for conditions like sepsis, acute coronary syndrome, and rheumatoid arthritis. Clinical studies have explored its efficacy in mitigating inflammation and improving outcomes in patients with severe infections or cardiovascular events. Additionally, its role in reducing tissue damage and inflammation in snakebite envenomation has been studied, offering a novel approach to managing venom toxicity. Ongoing research continues to evaluate its broader applications in inflammatory and critical care settings.